#94057
Re: Farmas USA
Coño NVAX verde :-)..por no llorar
NVAX
Se está hablando de:
#94058
Re: Farmas USA
Si nos fiamos de los datos de Nasdaq.com, ayer hubo un tío que vendió a $8.34 en AH más de una hora después que soltaran las news... al que compró (si no es un error) le tomaron bien el pelo.
#94059
Re: Farmas USA
Empieza el espectáculo
PT lowered from $14 to $2 at Wedbush
NVAX
#94060
Re: Farmas USA
Piper Jaffray va más allá y deja el PT en $1...
Piper Jaffray downgraded Novavax from Overweight to Neutral with a price target of $1.00 (from $14.00)
NVAX
#94061
Re: Farmas USA
Valor en cash y va que te matas (1,15-20 calculo para 30/09, si descuentas ya los intereses de los bonos convertibles pues 1$). La tecnología vale 0 para estos tipejos.
#94062
Re: Farmas USA
de Bioinvest
"Novavax also reported topline results from the Phase II rollover clinical trial of its RSV F Vaccine in older adults. The trial was a randomized, observer-blinded, placebo-controlled rollover trial that enrolled 1,329 older adults from the prior Phase II trial, conducted at the same 10 sites in the United States.
The rollover trial demonstrated immunogenicity in all active vaccine recipients. The event rate comparisons made to either placebo groups suggested that the second season immunization was protective, even in a year with a very low attack rate.
This is a little more promising and also conflicts somewhat with the Phase III study results. Further understanding of these data may come with full evaluation of the immune responses."
#94063
Re: Farmas USA
XOMA
El resumen de la conferencia de ayer se ve bien aquí; refleja bien la hora y pico que se tiraron sin decir prácticamente nada.
Mi traducción: tenemos una cosa que parece que funciona cuando aumentamos la dosis, pero aún tenemos que definirlo y está por ver. Ni siquiera queda claro el establecimiento de la dosis.
Su comunicado es mucho más encantador. Extraigo lo siguiente:
The initial data from the XOMA 358 Phase 2 clinical studies confirms that our first-in-class allosteric antibody is exhibiting an inhibition on insulin signaling, the desired mechanism-of-action. This means that for patients who are not able to properly regulate their high insulin levels and experience severe bouts of hypoglycemia, such as those diagnosed with congenital hyperinsulinism and certain post-bariatric surgery patients, XOMA 358 could provide benefit in preventing hypoglycemic episodes
“When we consider the totality of preclinical and clinical evidence, which demonstrates that XOMA 358 down-regulates insulin signaling by binding to the insulin receptor in an allosteric manner, we believe XOMA 358 is ready for advancement into Phase 2b multi-dose studies.
“The data from our ongoing Phase 2 study is helping us define the parameters that will give us the best opportunity for demonstrating efficacy in future studies, such as the use of continuous glucose monitoring to track glycemic profile on a continuous basis over days and weeks.”
#94064
